The 2nd Chronic Kidney Disease Drug Development (CKD3) focuses exclusively on overcoming challenges limiting the development of more efficacious and disease-modifying drugs against diabetic nephropathy, genetic and glomerular kidney disease.
Incorporating insights from 25+ industry leading speakers, this uniquely specific forum assesses key clinical and translational hurdles and the hottest emerging research necessary to achieve the potential of next-generation CKD drugs.
Join 80+ of your colleagues to accelerate the development of SGLT-2 inhibitors, antagonists of renal fibrosis and more, and advance the clinical validity and commercial viability for next-generation standards of care.
Speakers: George Bakris, University of Chicago, Vlado Perkovic, The George Institute Australia, Matthias Kretzler, University of Michigan, Jyothis George, Boehringer Ingelheim, Pernille B. Laerkegaard Hansen, AstraZeneca, Matthew Breyer, Janssen Research and Development, Lori Gowen Morton, Regeneron Pharmaceuticals, Curtis Rambaran, Daiichi Sankyo, Fabio Dorigotti, Vifor Pharma, Radko Komers, Retrophin, Colin Meyer, Reata Pharmaceuticals, Carol Moreno Quinn, AstraZeneca, Bergur Stefansson, AstraZeneca, Barbara Gillespie, University of North Carolina, Melissa West, American Society of Nephrology, Anna Greka, Brigham and Women’s Hospital, John Brennan, AbbVie, Gigi Shafai, Akebia Therapeutics, Rahul Kakkar, Corvidia Therapeutics, Harry Alcorn, Diamedica, Dario Lemos, Brigham and Women's Hospital, Steven Coca, Mount Sinai, Darren Kelly, Certa Therapeutics, Guangping Gao, University of Massachusetts Medical School, Benjamin Freedman, University of Washington, Nichole Jefferson, KHI Patient Family Partnership Council, Tim Johnson, UCB, Lesley Inker, Tufts University School of Medicine
Conference + 2 Workshops: USD 4097.0
Conference + 1 Workshop: USD 3498.0
Conference Only: USD 2899.0
Workshop Only: USD 699.0
Time: 8:00 am to 5:00 pm
Venue Name: Revere Hotel Boston Common